New safety test aims to unlock Life-Improving drug for type 1 diabetes
NCT ID NCT07225465
Summary
This study aims to make a promising diabetes drug safer for people with type 1 diabetes. The drug, Dapagliflozin, helps control blood sugar and weight but carries a risk of a dangerous condition called diabetic ketoacidosis (DKA). Researchers are testing if using a continuous ketone monitor with a lower alarm threshold (1.0 mmol/L) is better than a higher one (1.5 mmol/L) at preventing DKA in 115 adults with type 1 diabetes. The goal is to find the best warning system so patients can get the drug's benefits without the serious risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health
Heidelberg, Victoria, 3084, Australia
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Baker Heart and Diabetes Institute
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.